Senior Director, Epidemiology at Gilead Sciences

Foster City, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Advanced degree in epidemiology, public health, or related field (implied by senior level and expertise)
Excellence in design and conduct of epidemiologic studies/analyses
Direct expertise in use of Real-World Evidence (RWE) at different stages of product development and commercialization processes
Ability to lead and manage cross-functional efforts and resources
Experience overseeing teams of observational research scientists
Strong knowledge of robust scientific methods and fit-for-purpose data resources
Expertise in regulatory use of RWE
Excellent communication skills for internal and external stakeholders, including regulators, payers, and providers

Responsibilities

Serve as the single point of accountability for the development, execution, and communication of the global RWE strategy supporting early-stage clinical development and post-authorization evidence requirements for a specific Inflammation product and its pipeline/lifecycle indications
Ensure the use of robust scientific methods and fit-for-purpose data resources for the timely execution of the RWE strategy, in alignment with the clinical development plan and broader Global Development Team (GDT) objectives
Provide functional perspective and subject-matter expertise, especially regarding regulatory use of RWE, as a member of the product GDT
Lead a team of observational research scientists to deliver, within time, budget, and quality standards, proactive RWE generation including natural history of disease, population characterization, assessment of treatment patterns and unmet need, development of external comparators, benchmarking of clinical outcomes, comparative safety and effectiveness research, and post-approval safety studies
Communicate effectively about the utility of RWE across the product lifecycle and drive use of study/analysis results to support internal and external decisions
Oversee a team of observational research scientists and advocate for appropriate resources to ensure timeliness, quality, and utility of RWE for stakeholders (e.g., regulators)
Advise on methodological approaches in support of payer and provider interactions
Serve as the key RWE subject matter expert within the GDT for the product(s) and all its indications across the development lifecycle, acting as a strategic partner to clinical development, medical, and commercial teams

Skills

Real-World Evidence

Real-World Data

Epidemiology

Clinical Development

Inflammation

RWE Strategy

Therapeutic Area

Global Development Team

Clinical Data Sciences

Gilead Sciences

Develops and commercializes biopharmaceuticals

About Gilead Sciences

Gilead Sciences focuses on discovering, developing, and commercializing medicines for various medical conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company conducts extensive research and development to create new therapies, which are then marketed to healthcare providers, hospitals, and pharmacies after receiving regulatory approval. Gilead differentiates itself from competitors through its strong commitment to R&D and strategic partnerships, such as with SAP Ariba, to enhance its operations and product offerings. The company's goal is to improve health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Foster City, CaliforniaHeadquarters

1987Year Founded

$15,873.6MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Risks

Increased competition in HIV treatment from ViiV Healthcare's expanding drug portfolio.

Regulatory scrutiny over drug pricing could impact Gilead's U.S. market operations.

Patent expirations, like Truvada's, lead to increased generic competition and revenue loss.

Differentiation

Gilead's lenacapavir is recognized as the 2024 Breakthrough of the Year for HIV care.

Partnerships with LEO Pharma and Tubulis enhance Gilead's focus on inflammatory and cancer therapies.

Gilead's commitment to health equity initiatives like COMPASS and HepConnect sets it apart.

Upsides

Gilead's strategic partnerships expand its reach in inflammatory and oncology drug markets.

Investment in digital health technologies enhances Gilead's R&D and patient engagement.

Focus on sustainability improves Gilead's operational efficiency and corporate reputation.

Land your dream remote job 3x faster with AI

Try Jobo Free